VBL Therapeutics News Releases http://ir.vblrx.com/ VBL Therapeutics News Releases en VBL Therapeutics Announces Presentations at the 2019 ASCO Annual Meeting and the BIO International Convention http://ir.vblrx.com/news-releases/news-release-details/vbl-therapeutics-announces-presentations-2019-asco-annual TEL AVIV, Israel , May 23, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the upcoming presentation of final results from the Phase 2 study of VB-111 in ovarian cancer at the American Society of Clinical Oncology ( ASCO ) 2019 Annual Meeting, to be held May 31 - June 4, Thu, 23 May 2019 09:00:00 -0400 VBL Therapeutics News Releases 8571 VBL Therapeutics Announces First Quarter 2019 Financial Results http://ir.vblrx.com/news-releases/news-release-details/vbl-therapeutics-announces-first-quarter-2019-financial-results Conference Call and Webcast at 8:30am Eastern Time Today TEL AVIV, Israel , May 15, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today announced financial results for the first quarter ended March 31, 2019 , and provided a corporate update. “As we continue to advance development of Wed, 15 May 2019 07:00:00 -0400 VBL Therapeutics News Releases 8551 VBL Therapeutics to Report First Quarter 2019 Financial Results on May 15 http://ir.vblrx.com/news-releases/news-release-details/vbl-therapeutics-report-first-quarter-2019-financial-results-may TEL AVIV, Israel , May 06, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio webcast Mon, 06 May 2019 08:00:00 -0400 VBL Therapeutics News Releases 8541 VBL Therapeutics Announces Year Ended December 31, 2018 Financial Results and Provides Corporate Update http://ir.vblrx.com/news-releases/news-release-details/vbl-therapeutics-announces-year-ended-december-31-2018-financial Development of Phase 3 product candidate VB-111 continues in ovarian cancer toward interim analysis at year-end 2019 and expands through investigator-sponsored trials in rGBM and colon cancer Signed strategic agreement for VB-201 for veterinary use; potential payments to VBL may exceed €50 million Thu, 28 Mar 2019 07:15:00 -0400 VBL Therapeutics News Releases 8516 VBL Therapeutics to Present at Upcoming Conferences in April http://ir.vblrx.com/news-releases/news-release-details/vbl-therapeutics-present-upcoming-conferences-april TEL AVIV, Israel , March 25, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announces that the Company will present data on its Phase 3 drug candidate VB-111, at the 2019 American Association for Cancer Research (AACR) Annual Meeting , to be held March 29 - April 3, 2019 at Mon, 25 Mar 2019 08:00:00 -0400 VBL Therapeutics News Releases 8506 VBL Presents New Data on Potential of VB-111 to Stimulate the Immune System and Drive Immune Cells to Infiltrate Tumor Microenvironment http://ir.vblrx.com/news-releases/news-release-details/vbl-presents-new-data-potential-vb-111-stimulate-immune-system Data Presented at Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer® TEL AVIV, Israel , March 19, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), today announced the presentation of human data indicating that the viral anti-cancer investigational therapy VB-111 Tue, 19 Mar 2019 07:00:00 -0400 VBL Therapeutics News Releases 8501 VBL Therapeutics to Report Fiscal Year 2018 Financial Results on March 28 http://ir.vblrx.com/news-releases/news-release-details/vbl-therapeutics-report-fiscal-year-2018-financial-results-march TEL AVIV, Israel , March 14, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announced that it will host a conference call and live audio Thu, 14 Mar 2019 08:00:00 -0400 VBL Therapeutics News Releases 8486 VBL Therapeutics to Present at the Society of Gynecologic Oncology (SGO) 50th Annual Meeting on Women's Cancer on March 18 http://ir.vblrx.com/news-releases/news-release-details/vbl-therapeutics-present-society-gynecologic-oncology-sgo-50th TEL AVIV, Israel , March 11, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class treatments for cancer, today announces that the company will present data on its Phase 3 Mon, 11 Mar 2019 04:00:00 -0400 VBL Therapeutics News Releases 8476 VBL Presents New Data on the Potential of its Novel VB-600 Platform for Nonalcoholic Steatohepatitis (NASH) and Rheumatoid Arthritis (RA) http://ir.vblrx.com/news-releases/news-release-details/vbl-presents-new-data-potential-its-novel-vb-600-platform TEL AVIV, Israel, Feb. 26, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT ), (the “Company”) today announced new data implicating the potential of its VB-600 platform of antibodies targeting MOSPD2 (motile sperm domain-containing protein 2) for treatment of various inflammatory Tue, 26 Feb 2019 08:00:00 -0500 VBL Therapeutics News Releases 8461 VBL Therapeutics Awarded $2.9 Million Non-Dilutive Grant by the Israel Innovation Authority http://ir.vblrx.com/news-releases/news-release-details/vbl-therapeutics-awarded-29-million-non-dilutive-grant-israel TEL AVIV, Israel , Feb. 20, 2019 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) (the “Company”) today announced that it has been awarded a non-dilutive grant of over 10 million New Israeli Shekels (approximately $2.9 million ) by the Israel Innovation Authority (IIA) for 2019.  The funds will Wed, 20 Feb 2019 08:00:00 -0500 VBL Therapeutics News Releases 8451